We are live on ! Find out more
RGC icon

Regencell Bioscience
RGC

3 hedge funds and large institutions have $171K invested in Regencell Bioscience in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,746% more capital invested

Capital invested by funds: $9.27K → $171K (+$162K)

4.57% more ownership

Funds ownership: 0.19% → 4.76% (+4.6%)

25% less funds holding

Funds holding: 4 → 3 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$224K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$4.56K
2
TRCT
Tower Research Capital (TRC)
New York
-$1.19K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$169K +$224K +610,014 New
BlackRock
2
BlackRock
New York
$2.5K – – –
Qube Research & Technologies (QRT)
3
Qube Research & Technologies (QRT)
United Kingdom
$122 – – –
Morgan Stanley
4
Morgan Stanley
New York
– -$4.56K -12,388 Closed
TRCT
5
Tower Research Capital (TRC)
New York
– -$1.19K -3,230 Closed

RGC Hedge Fund Activity: Q4 2023 in Review

3 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q4 2023, worth a combined $171K — up 1,746% from $9.27K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of RGC and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was UBS Group, opening a new position worth an estimated $224K. The largest seller was Morgan Stanley, exiting entirely with an estimated $4.56K sold.

  • 3 institutional investors held Regencell Bioscience (RGC) as of Q4 2023, down from 4 in Q3 2023.
  • Funds reported $171K of Regencell Bioscience stock for Q4 2023, up 1,746% quarter-over-quarter.
  • 1 fund opened new Regencell Bioscience positions in Q4 2023 and 2 closed out, a net change of -1 holder.
  • The largest Regencell Bioscience buyer in Q4 2023 was UBS Group, an estimated $224K added.
  • The largest Regencell Bioscience seller in Q4 2023 was Morgan Stanley, an estimated $4.56K sold.

Based on aggregated 13F filings for Q4 2023.